People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

About this update from Arrowhead Pharmaceuticals, Inc.

PASADENA, Calif., August 17, 2026--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that people in Germany who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) are the among first in the European Union to have a new treatment option to reduce dangerously high levels of triglycerides (TGs, a type of fat) in their bloodstream. Following its marketing authorization by the European Commission in June 2026, REDEMPLO® (plozasiran) is now listed in the Lauer-Taxe® database and thus able to be prescribed, dispensed and reimbursed in Germany. REDEMPLO is authorized for use alongside diet, by adults diagnosed with FCS based on clinical symptoms or a genetic test, unlike other treatments that can be used only after genetic confirmation. It is taken as a subcutaneous injection once every three months. "People living with FCS face a life-long risk of recurrent and potentially fatal acute pancreatitis, and the possibility to treat using plozasiran based on a clinical diagnosis, without requiring a genetic test, could shorten a diagnostic journey that is often long and frustrating. This process is accelerated still further when physicians remain aware of the combination of symptoms that suggest FCS," said Professor Ioanna Gouni-Berthold, Head of the Lipid Clinic and Lipid Research Clinic, University of Cologne. "The availability of plozasiran in Germany provides physicians with an important new option to treat this debilitating disease." "We are thrilled to bring REDEMPLO as a new treatment option in Germany for people living with genetically or clinically confirmed FCS," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. "While we are working to make plozasiran available for people living with FCS in several European countries over the coming months, Germany is our first focus in the European Union. We are glad to be able to support eligible people in Germany with this new treatment option, as we continue the relevant processes in other European countries." Regulatory approval for REDEMPLO was based on findings from the PALISADE study (NCT05089084), a Phase 3 placebo-controlled study to evaluate the efficacy and safety of plozasiran in 75 adults with genetically confirmed or clinically diagnosed FCS. The primary endpoint of the study was the median percent change from base...

View stock analysis, news, and events for Arrowhead Pharmaceuticals, Inc.